Hegseth Is Pushing Testosterone. The VA Already Struggled With HRT.

Key Points:

• The Pentagon's new initiative to screen and provide testosterone therapy to service members over 30 faces challenges due to the Department of Veterans Affairs' (VA) documented struggles in managing hormone-replacement therapy, including overprescription and inadequate follow-up care.
• Experts warn that routine testosterone screening in asymptomatic troops risks unnecessary treatment, which can suppress natural hormone production and reduce fertility, potentially causing long-term health issues requiring ongoing medical care after military service.
• The VA's 2018 review found many testosterone treatments were started without proper symptom documentation or repeated testing, violating clinical guidelines; although the VA claims to have implemented corrective measures, concerns remain about continuity of care when veterans transition from active duty.
• Critics highlight that the Pentagon's program neglects female service members and broader reproductive healthcare needs, including infertility treatments largely excluded from military health insurance, raising questions about the initiative's focus and potential political motivations.
• The Pentagon has not provided scientific evidence supporting the screening mandate or addressed the financial and health implications of widespread testosterone therapy, while some lawmakers call for more inclusive and research-based approaches to military reproductive health.